Read More

Praxis Precision Medicines Provides Update On Advancing Clinical Stage Portfolio; Recently Announced Licensing Partnership With Tenacia Biotechnology To Develop And Commercialize Ulixacaltamide In Greater China With Total Consideration Over $275M

Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-Paroxysmal Response (PPR) exceeds expectations; topline results expected in 1Q 2024 after completion of 45 mg

IONS

Read More

Praxis Precision Medicines Announces Licensing And Collaboration Agreement With Tenacia Biotechnology For Ulixacaltamide In Greater China; To Receive Proceeds Of $15M And Eligible To Receive Up To $264M In Milestone Payments As Well As Tiered Royalties

Collaboration leverages Tenacia's expertise in central nervous system drug development and commercialization and will address a significant unmet patient need Praxis to receive upfront proceeds of $15 million and is

PRAX